IRBM

IRBM is an integrated contract research organization headquartered in Pomezia, Italy, specializing in preclinical drug discovery across cancer, neurological disorders, infectious diseases, and rare diseases. Originally established in 1990 as a joint venture between Merck and Co. and Italian chemical company Sigma-Tau, IRBM became an independent dru... g discovery company in 2010, retaining the scientific team responsible for developing several marketed therapeutics including Isentress, Zolinza, Grazoprevir, and Zejula. The organization offers fully integrated drug discovery services spanning target identification and validation, hit finding, lead optimization, and clinical candidate nomination, working across modalities including small molecules, peptides, and antibodies. All research is conducted within a single, state-of-the-art facility designed to provide seamless transitions between disciplines. IRBM partners with pharmaceutical companies, biotech firms, and prominent research foundations, and holds ISO 14001 and ISO 45001 certifications reflecting its commitment to environmental and occupational health standards.Read More